These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30489690)

  • 1. Comparative analysis of marketed factor VIII products: reply.
    Reipert BM; Anzengruber J; Scheiflinger F
    J Thromb Haemost; 2019 Jan; 17(1):233-235. PubMed ID: 30489690
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative analysis of marketed factor VIII products: comment.
    Makris M; Farrugia A
    J Thromb Haemost; 2019 Jan; 17(1):232-233. PubMed ID: 30376211
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.
    Anzengruber J; Lubich C; Prenninger T; Gringeri A; Scheiflinger F; Reipert BM; Malisauskas M
    J Thromb Haemost; 2018 Jun; 16(6):1176-1181. PubMed ID: 29665242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.
    Healey JF; Parker ET; Lollar P
    J Thromb Haemost; 2018 Feb; 16(2):303-315. PubMed ID: 29197156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clogging up the pipeline: factor VIII aggregates.
    Sabatino DE
    Blood; 2020 May; 135(21):1825-1827. PubMed ID: 32437559
    [No Abstract]   [Full Text] [Related]  

  • 6. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et al.
    Biguzzi E; Siboni SM; le Cessie S; Baronciani L; Rosendaal FR; van Hylckama Vlieg A; Peyvandi F
    J Thromb Haemost; 2021 Jan; 19(1):310. PubMed ID: 33405387
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to: "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis".
    Baiges A; Reverter JC; García Pagán JC
    J Hepatol; 2023 Mar; 78(3):e111-e112. PubMed ID: 36509182
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products.
    Chun H; Pettersson JR; Shestopal SA; Wu WW; Marakasova ES; Olivares P; Surov SS; Ovanesov MV; Shen RF; Sarafanov AG
    J Thromb Haemost; 2021 Apr; 19(4):954-966. PubMed ID: 33527662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma transfusion in hemophilia. VIII. Effect of various plasma products on hemophilia A].
    van CREVELD ; MOCHTAR IA
    Ned Tijdschr Geneeskd; 1963 Jan; 107():155-9. PubMed ID: 14023830
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to the letter by Iorio.
    Mannucci PM; Peyvandi F; Rosendaal FR
    Haemophilia; 2017 May; 23(3):e248-e249. PubMed ID: 28429882
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.
    Farrugia A; Bansal M
    Blood Transfus; 2019 Jan; 17(1):85. PubMed ID: 29106355
    [No Abstract]   [Full Text] [Related]  

  • 12. [INACTIVATION OF BLOOD THROMBOKINASE IN THE PRESENCE OF PROTHROMBIN AND FACTOR VIII].
    SCHIMPF K; BRIEGER G; OSAMO NO
    Klin Wochenschr; 1964 Feb; 42():134-7. PubMed ID: 14152613
    [No Abstract]   [Full Text] [Related]  

  • 13. SIPPET: insights into factor VIII immunogenicity.
    Fallon PG; Lavin M; O'Donnell JS
    J Thromb Haemost; 2018 Jan; 16(1):36-38. PubMed ID: 29080389
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonhuman sugars cause factor VIII troubles.
    Hoffmeister KM
    Blood; 2022 Mar; 139(9):1262-1263. PubMed ID: 35238885
    [No Abstract]   [Full Text] [Related]  

  • 15. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
    Abraham S; Duncan EM
    Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII forges its own path.
    Pratt KP
    Blood; 2023 Jul; 142(3):217-219. PubMed ID: 37471109
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
    Megías-Vericat JE; Bonanad Boix S; Berrueco Moreno R; Mingot-Castellano ME; Rodríguez López M; Canaro Hirnyk M; Mateo Arranz J; Calvo Villas JM; Haya Guaita S; Mesegué Medà M; López Jaime F; Albo-López C; Palomero-Massanet A; Vilalta Seto N; Leciñena IL; Haro ARC; Poveda Andrés JL
    Thromb Res; 2022 Aug; 216():35-42. PubMed ID: 35696967
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparative evaluation of the quality of cryoprecipitate prepared from 350 ml versus 450 ml of whole blood and different methods of thawing of plasma: A prospective observational study.
    Sree Bhagavathi M; Prakash S; Chhabra G; Sahu A; Mishra D; Mukherjee S
    Transfus Clin Biol; 2023 Aug; 30(3):329-334. PubMed ID: 37321533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Willebrand factor and factor VIII in a healthy Brazilian population. Association with ABO blood groups.
    Valadares DF; Soares RRP; Di Giacomo G; Rocha T; Reichert CO; Bydlowski SP
    Thromb Res; 2020 Apr; 188():49-51. PubMed ID: 32058198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.